Introduction
Atherosclerosis is accompanied by progressive thickening of a vessel wall resulting from abnormal behavior of vascular cells in response to disturbed blood flow with inflammatory signals. Currently, to treat this disease it is common practice to reopen the blocked vessel with a stent; however, rapid re-occlusion (restenosis) occurs because the underlying problem of cell health is not addressed. Advances in vascular gene delivery over the past decade have demonstrated potential in addressing clinical issues that arise from restenosis by directly controlling the behaviors of the problematic cell types 1 . To date, viral vectors are the most effective gene delivery platform due to their high transfection efficiency; however, safety issues such as immunogenicity and pathogenicity inhibit the broader clinical implementation of these systems 2, 3 . To address these issues, cationic polymers and lipids have been explored as alternative delivery platforms due to their facile synthesis, tunable properties and demonstrated biosafety [4] [5] [6] .
However, low transfection efficiency in vascular cells (due to inefficient uptake) is considered to be a significant hurdle for clinical translation 7 . In particular, none of the current gene delivery platforms demonstrated successful transfection into pathological vascular smooth muscle cells (VSMCs). It is well known that overproduction of reactive oxygen species (ROS) is indicative of abnormal VSMC behavior 8, 9 , including the process of restenosis 10, 11 . However, the development of ROS-responsive polymeric nanocarriers that can target and deliver therapeutics into ROS-overproducing VSMCs is still quite limited 12 . Recently, Xia et al. demonstrated
an intracellular ROS-degradable cationic polymers containing thioketal units that effectively delivered plasmid DNA (pDNA) into cancer cells, suggesting that specific delivery to cells with high ROS is a feasible approach 13 . Several previous studies demonstrated that polyplexes formed from pDNA and polycations have high transfection efficiency 14 ; however, low affinity of these polycations to pDNA can result in premature dissociation of polyplexes under physiological conditions. This problem can be overcome by an increased ratio of polycation to pDNA (N/P ratio), but at the expense of increased cellular toxicity. Therefore, the successful clinical application of cellbased gene therapy requires a stable, non-viral polyplex system that addresses both the extra-and intracellular environmental barriers without compromising biocompatibility.
Here, we report the successful utilization of PEGylated, oligoproline peptide-derived nanocarriers to improve pDNA transfection into VSMCs that are overproducing ROS due to inflammatory activation [15] [16] [17] . Our nanocarrier is dualresponsive as it is programmed to react first to extracellular more desired properties, such as effective condensation with pDNA, serum stability, ROS degradability, pH responsiveness, hemocompability, cellular biocompatibility or improved transfection efficiency. This work represents a significant improvement over the current state-of-the-art delivery methods. The extracellular ROS-cleavable, pH-responsive polymer, mPEG 113 -b-CP 5 K-b-PDMAEMA 42 -b-P(DMAEMA 22 -co-BMA 40 -co-PAA 24 ) (PPDDBP) was synthesized by combined approach of bio-conjugation methods and controlled reversible addition−fragmentaƟon chain-transfer (RAFT) polymerization. The first block contains methoxy polyethylene glycol (mPEG) as a corona-forming hydrophilic block to shield the cationic poly(2-dimethylamino)ethyl methacrylate (PDMAEMA) block from nonspecific interactions with blood and tissue components until the polyplexes encounter a high ROS environment 21 . Though PEG shielding of polyplexes is known to reduce the efficiency of cellular uptake 22, 23 and endosomal escape 24 , pathophysiological stimuli, (including glutathione and MMPs) have been successfully employed for targeted dePEGylation of cationic polyplex to rescue drug and gene delivery capabilities 21, 22, 25 .
To induce dePEGylation under high ROS environments, a proline oligomer, cysteine-(proline) 5 -lysine (CP 5 K) peptide was chosen as an ROS degradable second block, based on our previous work [26] [27] [28] . The third block, hydrophilic PDMAEMA contains positively charged tertiary amines, which facilitate effective condensation of nucleic acids through interaction with negatively-charged phosphate groups 29 . The fourth block, a core-stabilizing hydrophobic terpolymer p(DMAEMA-co-BMA-co-PAA) is composed of N,N-dimethylaminoethyl methacrylate (DMAEMA), n-butyl methacrylate (BMA), and 2-propylacrylic acid (PAA). This terpolymer block is ampholytic in nature under physiological pH with approximately equimolar ratios of positively charged DMAEMA and negatively charged PAA, together with hydrophobic butyl methacrylate (BMA) 30, 31 . The low pH within the endosome triggers protonation of the negatively-charged PAA with a simultaneous increase in the positive charge of the DMAEMA. This increased positive charge destabilizes the polyplex core and causes membrane disruption, thereby enabling endosomal escape of the nanocarrier 22, 32, 33 . As a control, we used a non-ROS-cleavable polymer without the CP 5 K peptide to demonstrate enhanced uptake of these polyplexes under ROS rich environments. The polyplex nanocarrier was evaluated for its size, charge, morphology, ROS degradability, pDNA condensation, serum stability and blood compatibility. To demonstrate the feasibility of ROS-responsive gene delivery into pathogenic VSMCs, we additionally investigated cellular uptake, cytotoxicity, and in vitro transfection efficiency with human coronary artery smooth muscle cells (HCASMCs).
Materials and methods

Materials
All chemicals and reagents were purchased either from SigmaAldrich or Fisher Scientific, USA and used without purification unless otherwise noted. 2-propyl acrylic acid (PAA) 34 35 . In a 100 ml flask, mPEG 113 -OH (2 mmol, 10 g, M n =5K Da,), ECT (4 mmol, 1.045g ) and DMAP (10 mg) were dissolved in anhydrous dichloromethane (100 mL) by stirring at RT. Dicyclohexylcarbodimide (DCC, 4mmol, 0.82g) was then added to the solution and stirred for 48h under nitrogen atmosphere. The white precipitate of dicyclohexyl urea was filtered. The filtrate was concentrated under vacuum and further precipitated three times into cold diethyl ether. The precipitated polymer was dried under vacuum. 1 H NMR spectra revealed 81% conjugation of ECT to mPEG. The molecular weight (M n ) and polydispersity (PDI) of polymer were 5,300 and 1.05, respecively, as determined by gel permeation chromatography (GPC).
Synthesis of mPEG 113 -b-PDMAEMA 50 -ECT:
In a glass test tube, mPEG 113 -ECT (0.064 g, 0.012 mmol, M n 5,262), DMAEMA (0.27 ml, 1.17 mmol), and AIBN (0.21 mg, 0.0012 mmol) were dissolved in dioxane (5 mL) and degassed by purging with nitrogen for 30 minutes. The degassed solution was submerged in a preheated oil bath at 70 ○ C for 8 h. The final polymerization mixture was quenched by exposure to air at RT. The polymer was purified by precipitation into tenfold excess cold diethyl ether, and then dried under vacuum. The polymer M n and PDI were 14,800 and 1.55, respectively, as determined by GPC. , dioxane (4.5 mL) and DMF (1.5 mL) were placed in a dry ampoule, and the solution was degassed by bubbling nitrogen for 30 minutes. The polymerization was performed at 70 ○ C for 24 h. The crude polymerization mixture was purified by precipitation twice in cold diethylether. The polymer M n and PDI were 25,300 and 1.22, respectively, as determined by GPC.
Synthesis of mPEG
Polymer characterization
1 H NMR spectra of organic compounds and polymers were collected in CDCl 3 with a Brüker 400 MHz spectrometer. GPC (Agilent Technologies, Santa Clara, CA, USA) was used to determine the M n and PDI of polymers in dimethylformamide (DMF) + 0.1 M LiBr mobile phase at 60 °C through three serial Tosoh Biosciences TSKGel Alpha columns (Tokyo, Japan). A Wyatt miniDAWN TREOS light scattering (LS) detector (Wyatt Technology Corp., Santa Barbara, CA, USA) and Agilent refractive index (RI) detector were used to calculate absolute M n based on dn/dc values experimentally determined through offline injection into the RI detector.
Preparation and characterization of polymer micelles
To prepare polymer micelles, either lyophilized PPDDBP or non-cleavable PDDBP (10 mg) was dissolved in 200 μL of methanol, followed by addition of pH 4.0 buffer (200 μL). Micelle formation was induced by drop wise addition of pH 8.0 buffer (10 mL) to the magnetically stirred polymer suspension using a syringe pump. Polymer micelles were filtered through a 0.2 micron syringe filter just before size and zeta potential measurements by dynamic light scattering (DLS, Malvern Zetasizer Nano ZS, Malvern, UK). To measure critical micelle concentration (CMC) of PPDDBP micelles, a range of polymer concentration from 0.01 to 1 mg/mL in DPBS was prepared, and stability of micelles was measured by DLS 36 . ROS mediated cleavage of peptide and subsequent changes in zeta potential of micelles in PBS were determined in the presence of 4 mM SIN-1(a generator of peroxynitrite that decomposes into nitric oxide and superoxide in an aqueous solution).
Assessment of ROS-triggered detachment of PEG from PPDDBP by GPC
To confirm ROS-mediated dePEGylation of PPDDBP polymer through cleavage of CP 5 K peptide, lyophilized PPDDBP (10 mg/mL) was incubated with 1 mM SIN-1 in DPBS at RT for 16 h. The polymer solution was then lyophilized and dissolved into DMF to run in GPC. The cleavage of CP 5 K peptide was confirmed by comparing GPC chromatograms of PPDDBP before and after SIN-1 treatment.
Preparation and characterization of polyplexes
Lyophilized PPDDBP or noncleavable PDDBP polymer at various N/P ratios were mixed with pDNA (1.5 μg/mL) in a 100 mM citric acid/sodium citrate buffer solution (pH 4.0). After 30 min incubation at RT, polyplex formation was induced by addition of pH 8.0 buffer to raise the pH up to 7.4. The size and zeta potential (ζ) of the polyplexes (N/P 10) were determined using DLS (Malvern Zetasizer Nano ZS). To see ROS mediated dePEGylation of polyplexes, changes in zeta potential of polyplexes (N/P 10) were measured in the presence of SIN-1 (4 mM) over 24 h. Transmission electron microscopy (TEM) samples were prepared on carbon film-backed copper grid (Electron Microscopy Sciences, Hatfield, PA, USA) by addition of a polyplex solution (5 μL, N/P10) for 60 seconds, followed by dry blotting. Next, the samples were counter stained with filtered 3% uranyl acetate (5 μL) as a negative stain for 20 seconds and again blotted dry. The samples were then dried under vacuum overnight and imaged using a FEI Tecnai Osiris TEM at 200 kV.
Assessment of pDNA loading by agarose gel electrophoresis
The ability of PPDDBP to condense pDNA was assessed by agarose gel electrophoresis. The polyplexes at various N/P ratios (1, 2, 5, 10, 20, and 30) were loaded with 10 μg/mL pDNA, and the samples were run into 0.5% agarose gel containing 0.05 μg/mL ethidium bromide (EtBr). Naked pDNA was used as a positive control. The gel electrophoresis was performed in TAE (1X) buffer at 100 V for 30 min. The bands were visualized and imaged with a UV trans-illuminator.
Stability of polyplexes in the presence of serum and SDS decomplexation
PPDDBP polyplexes (N/P 10) were incubated in a high concentration (50% w/v) of fetal bovine serum (FBS) at 37 °C for 0.25, 0.5, 1, 2, 3, and 6 h. As a harsh control condition to prove the DNase protection capability of the polyplexes, a solution of sodium dodecyl sulfate (SDS, 1% w/v) was added to cause release of pDNA. The samples were analyzed by gel electrophoresis as described above.
Hemolysis assay
The blood cytocompatibility of polymer alone and pDNA/PPDDBP polyplexes was measured by a pH dependent hemolysis assay 24 . Briefly, red blood cells (RBCs) were isolated from anonymous, consenting human donors according to well established protocols 24 RBCs were centrifuged at 500g for 5 min, and supernatant was measured using the M100 Pro plate reader by recording the absorbance at 541 nm to determine the percent hemolysis of samples compared to the positive control treated with Triton-X-100.
Cell viability
Cell viability of HCASMCs was measured by a resazurin assay 37 .
HCASMCs were seeded in 24-well plates at a density of 4 × 10 
Cellular uptake of polyplexes by Flow Cytometry
To evaluate cellular uptake of polyplexes, HCASMCs (1.0 × 10 5 cells/well in a 12-well plate) were cultured in SMC medium (Cell Applications Inc) for 24h. Cells were then treated with lipopolysaccharide (LPS, 1 μg/mL) and interferon gamma (IFN)-γ (100 units/mL) in fresh culture media for 6h to induce ROS production. Polyplexes were prepared from either ROS cleavable PPDDBP or non-cleavable PDDBP (both with N/P 10) by loading fluorescein labeled pDNA (Mirus Bio) at a final concentration of 1.5 ug/mL. Cells with or without LPS/IFNγwere then incubated with these polyplexes (n=3) for 6 h, washed twice with DPBS, and detached with 0.05% trypsin. Cellular uptake of particles was measured by FACSCalibur flow cytometry (BD Biosciences) and analyzed with the BD Cell Quest ProTM software.
Imaging intracellular distribution of polyplexes by confocal laser scanning microscopy
To track intracellular localization of polyplexes, HCASMCs (1 x 10 4 cells/well) were cultured in a Falcon 8-well culture slide (BD Biosciences) for 24 h. HCASMCs were then treated with LPS (1 μg/mL) and IFN-γ (100 units/mL) in fresh culture media for 6h to induce ROS production. Polyplexes (N/P 10) were prepared by loading fluorescein labelled pDNA (Mirus Bio) at the final concentration of 1.5 ug/mL to ROS cleavable PPDDBP, and control PDDBP. HCASMCs with or without LPS/IFN-γ were incubated with the polyplexes with (n=3) for 6 h, and then treated with Lysotracker (Life Technologies, NY, USA) for 1h and imaged by confocal laser scanning microscopy (Nikon, TE2000). The confocal images were analyzed using ImageJ (NIH, Maryland, USA). For measuring in vitro plasmid uptake by HCASMCs, the average intensity by green fluorescent plasmids within the total individual cell area was measured for N=10~15 cells per each condition using ImageJ (NIH, US), and averaged for each condition.
In vitro transfection efficiency
In vitro transfection efficiency of polyplexes in HCASMCs was assessed by a luciferase gene reporter assay. HCASMCs were Please do not adjust margins
Please do not adjust margins cultured in 96-well plates (12,000 cells/well for ~70-80 % confluent) in SMC medium for 24h. Cells were then treated with LPS (1 μg/mL) and IFN-γ (100 units/mL) for 6 h to induce ROS production, followed by treatment with PPDDBP and LF2K polyplexes at N/P 10 ratio for 24 h at 37 o C. Luciferin (150 μg/mL) was added to the samples, and bioluminescence from cells was measured using a Xenogen IVIS Imaging system 200 series (Perkin Elmer, Waltham, MA, USA). Cells were then washed twice with DPBS and lysed with 200 μL of lysis buffer (Promega, Madison, WI, USA). The protein content was using a microBCA protein assay reagent kit (Pierce) and reading absorbance at 562 nm using the M1000 Pro platen reader. The luciferase expression was reported in relative light units (RLU) normalized to mg protein (RLU/mg).
Statistical analysis
The experimental results are reported as means ± standard error mean (SEM). Data from each experiment were initially analyzed using single factor analysis of variance, and comparisons between individual samples were then performed using an unpaired Student's t-test. For all statistics p < 0.05 was considered significantly different.
Results and Discussion
Polymer synthesis and characterization
The ROS-cleavable oligo-proline peptide (CP 5 K) conjugated PEGylated copolymer, PPDDBP was synthesized as described in Scheme 1. First, the oligo-proline peptide (SH-CP 5 K-NH 2 ) containing five proline units (P 5 ) between a thiol (-SH) group of cysteine at one end and a primary amine (-NH 2 ) of lysine at the other terminus was synthesized by fluorenylmethyloxycarbonylchloride (FMOC)-based peptide synthesis 26 . The formation of the CP 5 K peptide was confirmed by the presence of single characteristic mass peak at m/z 776 in LC-MS spectrum (Fig. S1 , ESI †). The peptide, CP 5 K was conjugated with 5 kDa maleimide-functionalized methoxypolyethylene glycol (mPEG 113 -MAL) through the thiol group of cysteine end by maleimide-thiol coupling chemistry. The conjugation of mPEG 113 -b-CP 5 K-NH 2 was confirmed by a left-shift in the GPC chromatogram (Fig. 1) . Second, in order to build the other polymer blocks on this mPEG-peptide conjugate, the amine group of mPEG 113 The numbers of repeating DMAEMA, BMA, and PAA units in the random terpolymer block of the final copolymer were calculated by relative integration of the mPEG block peak at 3.65 ppm with CH 2 protons from DMAEMA, BMA and PAA at 4.15, 4.0 and 1.2 ppm, respectively (Table 1 , Fig. S2 , ESI †) 22 .
To prepare non-cleavable control polymer mPEG 113 -b-PDMAEMA 50 -b-P(DMAEMA 16 -co-BMA 42 -co-PAA 17 ) (PDDBP) without the CP 5 K peptide, the first terminal hydroxyl group of 5K mPEG was conjugated with the carboxylic group of ECT by a DCC/DMAP method, producing mPEG 113 -ECT as a RAFT macro CTA. This CTA was used to further build the second block as PDMAEMA. Subsequently, mPEG 113 -b-PDMAEMA 50 -ECT was utilized for the third block as p(DMAEMA-co-BMA-co-PAA) random copolymer under similar polymerization conditions as described for PPDDBP (Scheme S1, Table S1 , Fig. S3, Fig. S4 , ESI †).
Preparation and characterization of polymer micelles
In aqueous media, ROS-responsive PPDDBP and uncleavable PDDBP assembled into stable micelles through hydrophilic PEG and PDMAEMA as corona and hydrophobic p(DMAEMA-co-BMA-co-PAA) as core forming block with an average diameters of 37 and 46 nm, respectively (Fig. S5A, ESI †) . Their ζ-potential values were 1.54 mV and 0.9 mV (Fig. S5B , ESI †), respectively, indicating mPEG-mediated shielding of positively-charged PDMAEMA. The PPDDBP micelles were stable down to 0.1 mg/mL concentration but were destabilized at 0.01 mg/mL concentration. This observation indicates that the CMC of these micelles is between 0.1-0.01 mg/mL (Fig. S6 , ESI †).
Confirmation of ROS-triggered dePEGylation of PPDDBP
To confirm ROS-mediated dePEGylation of the nanocarrier, PPDDBP copolymer micelles were incubated overnight with a 1 mM dose of SIN-1, a producer of peroxynitrite 39, 40 , in DPBS at pH 7.4. Fig. 2 shows GPC chromatograms of mPEG 113 -MAL and PPDDBP polymer before and after SIN-1 treatment. In the presence of SIN-1, a clear decrease in the polymer molecular weight with an appearance of a mPEG shoulder peak indicates ROS-mediated dePEGylation of polymer micelles through cleavage of CP 5 K peptide. DePEGylation also increased the ζ-potential from 1.54 mV to 8.45 mV for PPDDBP micelles (Fig.  S5B , ESI †) over a 20 hour incubation with 4 mM concentration of SIN-1. In contrast, the zeta potential of the control PDDBP micelles remained unchanged (Fig. S5B, ESI †) . The increase in the zeta potential of the PPDDBP micelles compared to control (PDDBP) after SIN-1 treatment suggests that the cleavage of mPEG block from PPDDBP results in an exposure of the positively-charged amine groups of the PDMAEMA block in aqueous solution. To investigate the effect of SIN-1 mediated dePEGylation on size and stability of micelles, PPDDBP polymer micelles (1 mg/mL) in DPBS (pH 7.4) were incubated with SIN-1 (4 mM) for 24h. DLS measurement indicated that the size of polymer micelles (47 nm) remained unchanged after SIN-1 treatment, indicating the micelle stability was maintained by hydrophilic PDMAEMA corona and hydrophobic P(DMAEMA-co-BMA-co-PAA) core. (Fig. S7, ESI †) . 
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These results suggest that in ROS-rich microenvironments, the PPDDBP micelles would improve cellular uptake by triggering the interaction of positively-charged polymer micelles with the negatively-charged plasma.
Preparation and characterization of PPDDBP/pDNA polyplexes
The size and ζ-potential of polyplexes were measured to determine their compatibility for intravenous delivery 41 . To determine the stability of the polyplexes (N/P 10), we used DLS to characterize the size distribution, and observed a unimodal peak with an average diameter of 120 nm (Fig. 3A) . The size distribution of polyplexes was further examined by TEM, which confirmed monodisperse particles with spherical morphology (Fig. 3B) . The smaller size of the polyplexes in the TEM image compared to that measured by DLS can be explained by dehydration of the hydrophilic segments during TEM sample preparation 42 .
To further verify the ROS-mediated dePEGylation from polyplexes, PPDDBP/pDNA polyplexes (N/P 10) were incubated overnight with SIN-1 under similar condition as described for PPDDBP micelles in Fig. 4 . The polyplex showed an increase in ζ-potential from 1.55 mV to 8.75 mV after SIN-1 treatment. This observation indicates the polyplexes can undergo dePEGylation in response ROS overproduction, thereby improving cellular uptake through enabling positively charged PDMAEMA to interact with the negatively charged plasma membrane of target cells 21, 43 .
The condensation of PPDDBP with pDNA was examined by gel electrophoresis at various N/P ratios (1, 2, 5, 10, 20, and 30) and compared to free pDNA to determine the minimum amount of PPDDBP polymer required for effective polyplex formation with pDNA (Fig. S8, ESI †) . Regardless of the N/P ratios, all the polyplex groups showed no free pDNA, which indicates effective condensation of pDNA 44 . To investigate the stability of polyplexes and protection of pDNA in serum, PPDDBP/pDNA polyplexes at N/P 10 ratios were incubated with 50% serum for 0.25, 0.5, 1, 2, 3, and 6 h. As shown in Fig.  S9 , ESI †, a complete retention of pDNA within polyplexes was observed whereas free pDNA degraded in the presence of serum. In another gel experiment, protection of pDNA from serum-derived DNAses by PPDDBP was accessed by addition of 1% SDS to release pDNA from polyplexes in incubation with 50% serum. Notably, a solution of SDS (1% w/v) solution in PBS was added to each sample to release the pDNA from polyplexes. The appearance of released pDNA bands with persistent intensity relative to free pDNA in PBS indicates PPDDBP completely protected pDNA from FBS-derived DNAses at 37 °C (Fig. S9 , ESI †).
A major barrier to intracellular gene delivery is entrapment and degradation of polyplexes in the endo-lysosomal pathway 45 . To test if our nanocarrier can overcome this hurdle, hemolysis of the nanocarrier before and after polyplex formation was evaluated with three different polymer concentrations (1, 5, and 40 μg/mL) at four different pH conditions (7.4. 6.8, 6.2 and 5.8) that mimic extracellular and endo-lysosomal trafficking 24 . As shown in Fig. S10 , ESI †, minimal hemolysis of RBCs was observed for all test concentrations at pH 7.4 compared to Triton-X-100 (positive control) indicating excellent hemocompatibility of PPDDBP under physiological conditions. Both polymers alone (Fig.  S10A , ESI †) and polyplexes (Fig. S10B , ESI †) increased hemolysis of RBCs as pH decreased from 7.4 to 5.8. This result indicates that polyplexes can rupture RBC membranes at endosomal pH, thereby enabling successful escape from endolysosomal degradation.
Cytotoxicity assay
Cytotoxicity is a major limitation of liposomes, the most widely accepted delivery platform. Therefore, cytocompatibility of polyplexes prepared at different N/P ratios (1, 2, 4, 8, 10 and 20) with HCASMCs was evaluated by resazurin assay (Fig. 5 ) 37 . Cells showed more than 85% cell viability with PPDDBP polyplexes (N/P ratio at and below 10) while lipofectamine 2000 (LF2K) exhibited significantly lower cell viability. This result suggests better cytocompatibility of PPDDBP/pDNA polyplexes compared to commercial LF2K polyplexes under similar environments.
Measurement of Intracellular ROS production in HCASMCs
ROS are overproduced when VSMCs become dysfunctional under pathological vascular environments. Thus, ROS overproduction is likely an effective pathological stimulus for triggering therapeutic release from delivery systems 9 . To generate an in vitro model of oxidative stress, ROS production of HCASMCs was induced by treatment of LPS (1 μg/mL) and IFN-γ (100 units/mL) for 6h 26 . Intracellular ROS production was then measured by CM-H 2 DCFDA staining with flow cytometric analysis 38 . LPS/IFN-γ-treated HCASMCs showed a significant shift in the mean fluorescence intensity of intracellular CM-H 2 DCFDA when compared with untreated HCASMCs (Fig. 6 ). These conditions were used to test ROS-responsive pDNA transfection of polyplexes.
Cellular uptake of polyplexes
To test if CP 5 K cleavage in an ROS-rich environment would improve nanoparticle uptake and subsequent transfection, cellular uptake of polyplexes prepared by condensation of fluorescein-labeled pDNA either with ROS-cleavable PPDDBP or control PDDBP was quantitatively determined by flow cytometry (Fig. 7A ) LPS/IFN-γ-treated HCASMCs showed improved uptake of PPDDBP polyplexes when compared to untreated HCASMCs or PDDBP conditions. This result suggests that ROS overproduction of HCASMCs in response to LPS/IFN-γ treatment induced dePEGylation of PPDDBP through CP 5 K peptide and thereby resulted in exposure of cationic PDMAEMA. These processes improved cellular uptake. Confocal microscopy images (Fig. 7B ) and quantitative image analysis (Fig. 7C) showed that pDNA (green) was sequestered to endosomes (red) for untreated HCASMCs with PPDDBP, or with either control PDDBP condition, as evidenced by colocalization of the two colors. In stark contrast, treated HCASMCs with PPDDBP exhibited free pDNA within the cell, indicating that the pH-responsive nature of the underlying polyplex core was active once dePEGylation occurred, thereby enabling lysosomal escape of polyplexes.
In vitro gene transfection
Transfection efficiency of PPDDBP/pDNA polyplexes with and without LPS /IFN-γ treatment was further evaluated in HCASMCs using a luciferase reporter (Fig. 8 ). PPDDBP polyplexes (N/P 10) were compared with commercially available lipofectamine (LF2K) as a positive control. The transfection efficiency of PPDDBP polyplexes was about 2.5 fold higher in HCASMCS pretreated with LPS/IFN-γ than that of untreated HCASMCS or commercially-available LF2K. The excellent cytocompatibility and higher cellular uptake of polyplexes under ROS-rich environments contributed to high transfection efficiency in HCASMCs when treated with LPS/IFN-γ. 
Conclusions
In summary, the present study demonstrates the use of a new ROS-responsive polyplex nanocarrier as a non-viral gene delivery platform for targeting pathological vascular microenvironments that exhibit high levels of oxidative stress. A dual ROS and pH-responsive polyplex nanocarrier was synthesized by a combination of site-specific orthogonal bioconjugation and RAFT polymerization methods, and was characterized for use in gene delivery applications. ROSmediated dePEGylation of the polyplex nanocarrier was confirmed by the increase in ζ-potential in DLS and the appearance of a PEG shoulder in the GPC chromatogram. The polyplexes were shown to maintain hemolytic capability at endosomal pH and to protect pDNA from DNAses at a high serum concentration. When ROS was overproduced in HCASMCs in response to LPS/IFN-γ treatment, higher cellular uptake of polyplexes and enhanced transfection of pDNA were observed, compared with the controls. The collective data suggests the functional significance of this polyplex nanocarrier as a new class of dual stimuli-responsive polyplex platform for intravascular gene delivery.
